

U.S. Patent Application No. 10/681,352
Amendment dated September 16, 2008
Reply to Office Action of July 18, 2008

RECEIVED
CENTRAL FAX CENTER
SEP 16 2008

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 24 (Canceled)

25. (Previously presented) A method for determining treatments for a cancer patient, comprising:

determining what amino acids are encoded by ~~one or more of positions 21, 9, 6, 5, 4, 3, 9, 14, 19, 23, 26, 30, 37, 38, 45, 53, 55, 56, 57, 66, and 67, 70, 71, 74, 77, 84, 85, 86, 87, 89, 90, 116, 125, 130, 140, 182, 197, 220, 221, and 224~~ of the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene of the patient;

~~determining what amino acids are encoded by one or more of positions 25, 24, 17, 16, 1, 9, 10, 11, 13, 14, 16, 25, 26, 28, 30, 31, 32, 33, 37, 38, 40, 47, 57, 60, 67, 70, 71, 73, 74, 77, 78, 85, 86, 96, 98, 104, 120, 133, 142, 166, 231, and 233, of the DRB1* (Major histocompatibility complex, class II, DR beta 1) gene of the patient;~~

~~—determining what amino acids are encoded by one or more of positions 8, 9, 11, 35, 36, 55, 56, 57, 65, 69, 76, 84, 85, 86, and 87, of the DPB1* (Major histocompatibility complex, class II, DP beta 1) gene of the patient; and~~

determining a cancer treatment immunotherapy to have having a statistically significant probability of prolonging the cancer patient's survival, ~~wherein the determination of a cancer treatment is based on the amino acids~~ when Asp is encoded at the positions position 57 and Val is encoded at position 67 of the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene, ~~the DRB1* (Major histocompatibility complex, class II, DR beta 1) gene, and the~~

U.S. Patent Application No. 10/681,352
Amendment dated September 16, 2008
Reply to Office Action of July 18, 2008

~~DPB1* (Major histocompatibility complex, class II, DP beta 1) gene of the patient, wherein the cancer treatment comprises immunotherapy, chemotherapy, resection, or a combination thereof;~~
wherein the cancer of the patient comprises stomach cancer.

26. Canceled.

27. (Withdrawn) A method for determining treatments for a cancer patient, comprising:

determining what amino acids are encoded by positions -9, 19, 26, 85, 89, 90, and 116 of the HLA DQB1 *gene of the patient;

determining what amino acids are encoded by positions 14, 25, 47, and 78, of the DRB1 *gene of the patient;

determining what amino acids are encoded by positions 9, 36, 55, 69, and 76, of the DPB1 *gene of the patient; and

correlating the amino acids encoded at the positions with a cancer treatment having the greatest statically significant probability of prolonging the cancer patient's survival, wherein the cancer treatment comprises immunotherapy, chemotherapy, resection, or a combination thereof.

28. (Withdrawn) The method of claim 27, wherein the cancer patient comprises stomach cancer.